key: cord-0889358-t5f3llzr authors: Rakusa, Martin; Öztürk, Serefnur; Moro, Elena; Helbok, Raimund; Bassetti, Claudio L.; Beghi, Ettore; Bereczki, Daniel; Bodini, Benedetta; Di Liberto, Giovanni; Jenkins, Thomas M.; Macerollo, Antonella; Maia, Luis F.; Martinelli‐Boneschi, Filippo; Pisani, Antonio; Priori, Alberto; Sauerbier, Anna; Soffietti, Riccardo; Taba, Pille; von Oertzen, Tim J.; Zedde, Marialuisa; Crean, Michael; Burlica, Anja; Cavallieri, Francesco; Sellner, Johann title: COVID‐19 vaccination hesitancy among people with chronic neurological disorders: A position paper date: 2022-05-10 journal: Eur J Neurol DOI: 10.1111/ene.15368 sha: 36f46bd4830fa9f3ef1b8d1b733efd52a2eb80a4 doc_id: 889358 cord_uid: t5f3llzr BACKGROUND AND PURPOSE: Health risks associated with SARS‐CoV‐2 infection are undisputed. Moreover, the capability of vaccination to prevent symptomatic, severe, and fatal COVID‐19 is recognized. There is also early evidence that vaccination can reduce the chance for long COVID‐19. Nonetheless, the willingness to get vaccinated and receive booster shots remains subpar among people with neurologic disorders. Vaccine scepticism not only jeopardizes collective efforts to end the COVID‐19 pandemic but puts individual lives at risk, as some chronic neurologic diseases are associated with a higher risk for an unfavorable COVID‐19 course. METHODS: In this position paper, the NeuroCOVID‐19 Task Force of the European Academy of Neurology (EAN) summarizes the current knowledge on the prognosis of COVID‐19 among patients with neurologic disease, elucidates potential barriers to vaccination coverage, and formulates strategies to overcome vaccination hesitancy. A survey among the Task Force members on the phenomenon of vaccination hesitancy among people with neurologic disease supports the lines of argumentation. RESULTS: The study revealed that people with multiple sclerosis and other nervous system autoimmune disorders are most skeptical of SARS‐CoV‐2 vaccination. The prevailing concerns included the chance of worsening the pre‐existing neurological condition, vaccination‐related adverse events, and drug interaction. CONCLUSIONS: The EAN NeuroCOVID‐19 Task Force reinforces the key role of neurologists as advocates of COVID‐19 vaccination. Neurologists need to argue in the interest of their patients about the overwhelming individual and global benefits of COVID‐19 vaccination. Moreover, they need to keep on eye on this vulnerable patient group, its concerns, and the emergence of potential safety signals. Vaccination is the most cost-efficient method to avoid infectious diseases and mitigate the rate of detrimental outcomes [1] . Moreover, immunization campaigns have been one of the most effective public health interventions so far [2, 3] . Since the global outbreak of coronavirus disease 2019 (COVID- 19) , researchers worldwide have been working tirelessly and collaboratively to develop vaccines against this highly contagious RNA virus. The real-world effectiveness of the vaccines against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), the pathogen that causes COVID-19, has been corroborated on a scientific basis. The findings are consistent with and complement the estimates of vaccine efficacy from phase 3 trials with regard to the prevention of symptomatic, severe, and fatal disease [4] . However, the protection against SARS-CoV-2 infection and nonsevere disease wanes over time. This is particularly evident in the elderly population and in those treated with immunosuppressive drugs. Subsequently, regular booster shots are required to maintain the efficacy of protection against COVID-19 [5] . People with the debilitating condition termed long COVID-19 continue to experience symptoms weeks, months, or years after SARS-CoV-2 infection. Up to 30% of infected people, including many who were never hospitalized, have persistent symptoms, which include breathlessness, headache, chest pain, abdominal symptoms, myalgia, and fatigue. Furthermore, cognitive difficulties, anxiety, and depression are additional reported conditions. There is also early scientific evidence of the capability of COVID-19 vaccines to reduce the chance of long COVID-19 [6, 7] . The underlying mechanism of action is still under investigation; a shorter time of presence of the virus in the body and a weaker immune reaction in vaccinated individuals are among the possible explanations. On the global level, the effectiveness of the vaccination against SARS-CoV-2 depends on its uptake. If there are individuals who decline to be immunized, the vaccination coverage and subsequent goal of ending the pandemic are jeopardized. A mathematical modeling study disclosed that a refusal rate of >10% is estimated to be sufficient to weaken the population benefits of vaccination against COVID-19 [8] . Notably, the unvaccinated are a threat to the vaccinated, as they can be the breeding ground for aggressive SARS-CoV-2 variants resistant to current vaccines [9] . Most European countries' vaccination and boostering rates by the end of 2021 are not sufficient to stop the pandemic [10] . Subsequently, several countries returned to measures such as lockdowns and travel restrictions. At the same time, backed by the right to health, some European countries will enforce mandatory vaccination for the entire adult population, vulnerable individuals, or specific workplace settings such as health care providers [11] . At the beginning of 2020, the European Academy of Neurology (EAN) established the EANCore NeuroCOVID-19 Task Force to support neurologists in Europe and beyond to prepare for and manage the challenges of this global crisis [12] . The Task Force consists of neurologists from different subspecialties and represent all parts of Europe (Central, Eastern, Southern, Western Europe). Details on previous projects and activities are provided at https://www.ean. org/ean/eanco re-covid -19. In this position paper, the Task Force (a) summarizes the current knowledge on the prognosis of COVID-19 among patients with neurological disease, (b) discusses potential barriers to vaccination coverage, and (c) formulates strategies to overcome vaccination hesitancy. A survey on vaccination hesitancy in people with neurologic disease among the Task Force members discloses further aspects and supports the lines of argumentation. Individuals with certain neurological comorbidities are at risk for an unfavorable course of SARS-CoV-2 infection [13] [14] [15] [16] [17] [18] . For instance, a recent meta-analysis revealed that patients with prior cerebrovascular disease who had a SARS-CoV-2 infection had a higher risk of severity (odds ratio [OR] = 3.10, 95% confidence interval [CI] = 2.21-4.36, p < 0.001) and mortality (OR = 3.45, 95% CI = 2.46-4.84, p < 0.001) [13] . Another meta-analysis, this one focusing exclusively on epilepsy, disclosed that these patients are at higher risk for increased severity (OR = 1.69, 95% CI = 1.11-2.59, p = 0.010) and mortality from COVID-19 (OR = 1.71, 95% CI = 1.14-2.56, p = 0.010). A meta-analysis in patients with dementia as comorbidity also found a higher rate of poor outcome with COVID-19 [18] . Parkinson disease was also associated with poor COVID-19 in-hospital outcomes (OR = 2.64, 95% CI = 1.75-3.99, p < 0.00001) [18] . The risk factors for lethality related to COVID-19 in people with multiple sclerosis (MS) include the progressive disease stage and ongoing treatment with anti-CD20 agents [19] [20] [21] . Moreover, COVID-19 may activate neuroinflammatory and neurodegenerative pathways, leading to the emergence of nervous system disorders and progression of the underlying neurological disease [22] . S A R S -C oV-2 VACCINATION: FROM EQUITABLE G LOBAL ACCE SS TO VACCINATION HE SITANC Y Early in 2021, our main concern for COVID-19 vaccination was to supply the vulnerable population and prevent unequal distribution [23, 24] . However, we are now facing vaccine hesitancy, a phenomenon that the World Health Organization (WHO) listed among the top 10 global threats [25, 26] . Vaccine hesitancy refers to delay or unwillingness to get vaccinated despite the availability of vaccine services. It is influenced by factors such as complacency, convenience, and confidence [27, 28] . Vaccine skepticism in the context of COVID-19 is in part related to the selective interpretation of SARS-CoV-2 vaccine efficacy and unbiased coverage of side effects of vaccines [29] . The plethora of COVID-19-associated reports, the infodemic, an overabundance of information, some accurate and some not, makes it hard for people to find trustworthy sources and reliable guidance when they need it. Action to fight misinformation and increase transparency in all aspects cannot be implemented early enough. Patient stories regarding potential and medically unverified side effects on social media channels are growing in number and fuel vaccine skepticism. In this regard, functional neurological disorders with seizures or paralysis following vaccination are also found in the recent literature, calling for increased awareness of this condition [30, 31] . Directed misinformation, political interests, and disagreement among experts further complicate vaccine coverage efforts. Adverse events related to immunization can occur with any vaccine and are a significant source of vaccine hesitancy. Clinical manifestations of side effects include fever/chills, headache, fatigue, myalgia, and arthralgia, or local injection site effects like swelling, redness, or pain. An adverse event following immunization is considered severe if it results in death or significant persistent disability, is lifethreatening, requires in-patient hospitalization, or is a congenital anomaly/birth defect [32] . Neurological adverse events following COVID-19 vaccination are generally mild and transient and do not require hospital admission [33] . The WHO lists Guillain-Barré syndrome, seizures, anaphylaxis, syncope, encephalitis, thrombocytopenia, vasculitis, and Bell palsy as serious neurologic adverse events. A large population-based study of more than 32 million people investigated the neurological adverse events associated with the ChAdOx1nCoV-19 (AstraZeneca, UK) and BNT162b2 (Janssen, Belgium) vaccines as well as SARS-CoV-2 infection [34] . First, they found an increased risk of hospital admission for Guillain-Barré syndrome (15-21 days and 22-28 days), Bell palsy (15-21 days), and myasthenic disorders (15-21 days) in those who received the ChAdOx1nCoV-19 vaccine. Second, an increased risk of hospital admission for hemorrhagic stroke (1-7 days and 15-21 days) was reported in those who received the BNT162b2 vaccine. Given the low incidence and mostly favorable outcome, the benefits of vaccinations outweigh the comparatively small risks of autoimmune adverse events [35] . In contrast, severe and sometimes fatal cerebral venous thrombosis cases, occurring predominantly in young women, have been reported within 4-28 days of vaccination [36] . This rare postvaccine entity was observed with the vector-based ChAdOx1nCoV-19 and Ad26.COV2.S SARS-CoV-2 vaccines is probably caused by platelet-activating antibodies against platelet factor 4, mimicking autoimmune heparin-induced thrombocytopenia and currently named vaccine-induced immune thrombotic thrombocytopenia (VITT) [37, 38] . However, even though decision-making can be supported by an advantageous risk-benefit profile from phase 3 trials and real-world evidence, vaccine skepticism is reported among people living with neurological disorders, for example, epilepsy and MS [39] [40] [41] [42] . Morover, diminished humoral immune responses after SARS-CoV-2 vaccination in people with neurological disorders on CD20-depleting agents and S1P receptor modulators call for individualized vaccination strategies [43] [44] [45] . The recommendation for COVID-19 vaccination and the definition of contraindications among treating doctors is not uniform, for example, for people with Parkinson disease [46, 47] . Nonetheless, vaccine hesitancy in people living with MS or autoimmune disorders of the nervous system is not unexpected. The rationale for skepticism is safety, a line of argumentation also brought forward by people living with Parkinson disease and epilepsy [40, [47] [48] [49] . The concerns are related to the fact that vaccination was previously implicated in the pathogenesis of MS and can trigger, although very rarely, central nervous system (CNS)/peripheral nervous system (PNS) autoimmunity. Although vaccination as the cause of MS has been refuted scientifically, a relapse or disease activation cannot be ruled out [50] . Reports of a first MS manifestation and relapses in established MS in temporal relation to the vaccine shots are available [51] [52] [53] . However, there are also reports that suggest that there is no increased risk of relapse activity among vaccinated patients with MS and that benefits outweigh the potential dangers of COVID-19 vaccination [54, 55] . Acute CNS or PNS demyelination is a known but infrequent complication of other vaccines and has also been observed in close temporal relation to SARS-CoV-2 vaccination [56, 57] . However, individual case reports are not suitable to establish any causality. Such observations must be viewed in relation to the vast number of people vaccinated against SARS-CoV-2 worldwide. Some patients assume distinct safety aspects for mRNA/ vector-based SARS-CoV-2 vaccines and are reluctant until inactivated vaccines are available. However, a study of 1165 people with neuroinflammatory disorders did not find any difference in patient-reported vaccine side effects and no evidence of disease worsening compared to controls after vaccination with these newer vaccines [58] . Taken together, even if the clinical trials of SARS-CoV-2 vaccination were not aimed at elucidating safety and efficacy in neurological disorders, no safety signals have been identified for this subgroup so far, and vaccination with the approved preparations can be regarded as safe. In December 2021, we conducted an online survey (Appendix S1) among the EANcore NeuroCOVID-19 Task Force members, consist- Table 2 . All experts discussed the rationale for COVID-19 vaccination with their patients. As a result, more than one third of them were commonly or always able to convince them to get vaccinated ( Table 1) . The frontrunners among the suggestions for increasing vaccination coverage were compulsory national vaccination strategies, information campaigns, uniformity among doctors, and trust in a patient-doctor relationship (Figure 2) . The introduction of attenuated vaccines was not seen as a significant means to increase the vaccination rate. Applying further vaccine shots in people with a history of SARS-CoV-2 vaccination-related neurological conditions was regarded as potentially more harmful for some conditions (Table 3) . These included acute demyelinating conditions (neutral, 39%; agree, 39%) and sinus vein thrombosis (neutral, 28%; agree and strongly agree, 39%). The rating for another jab after COVID-19 vaccinationassociated stroke was neutral for 33% but seen as harmful (34%) and not dangerous in about the same range (33%). No clear tendency could be derived for the other conditions. The respondents made no additional comments in the free text section. Our study explored several aspects of COVID-19 vaccination hesitancy among people living with neurological disorders by interviewing their treating neurologists. These findings are unique, as the survey was conducted 1 year after approval of the SARS-CoV-2 vaccines, and we surveyed neurologists with expertise in subspecialties and COVID- 19 Our study also illustrates the importance of neurologists as advocates of public health measures. Some experts could mitigate vaccine skepticism, which might be even higher in individuals who already declined vaccines in the pre-COVID-19 era. This observation is corroborated by a study of Portuguese people living with MS, which found that the most hesitant patients would consider being vaccinated following their physicians' advice [59] . This role as an advocate also needs to be extended to nurses and other health care workers [60] . A stable, trusted doctor-patient relationship will be crucial for further strategies to improve vaccine coverage. In this regard, the experts proposed uniformity among doctors and scientists and targeted information campaigns on various levels. The latter requires special attention, as studies on vaccine information from governmental agencies and professional societies were more challenging to read than the information provided by antivaccination campaigners [61] . Of note, the confrontation with severe COVID-19 outcome, in analogy to antismoking campaigns, was not the frontrunner to mitigate vaccine hesitancy. However, the experts believe that this gentle approach via information campaigns needs to be expanded by more This pilot study has limitations. The sample size is small and may be intrinsically biased toward doctors who promote vaccination. In addition, a majority of them work at tertiary care facilities. The members of the Task Force cover half of the European countries and major neurological fields [63, 64] . However, experts in headache, sleep disorders, and neuro-oncology were missing. get additional vaccine shots in the further course of the pandemic will play a key role in preventing individual detrimental outcomes and in bringing a closer end to the pandemic. Primary prevention of COVID-19: advocacy for vaccination from a neurological perspective Cost-effectiveness of adult vaccinations: a systematic review Clinical outcomes and cost-effectiveness of COVID-19 vaccination in South Africa Effectiveness of covid-19 vaccines over a 9-month period in North Carolina Safety and efficacy of a third dose of BNT162b2 covid-19 vaccine Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional study of patients tested between Planning for a COVID-19 vaccination program How the unvaccinated threaten the vaccinated for COVID-19: a Darwinian perspective COVID-19 compulsory vaccination and the European Court of Human Rights Mandatory COVID-19 vaccination and human rights NeuroCOVID: it's time to join forces globally Nervous system diseases are associated with the severity and mortality of patients with COVID-19: a systematic review and meta-analysis Neurological comorbidity is a predictor of death in covid-19 disease: a cohort study on 576 patients Neurological comorbidity and severity of COVID-19 Epilepsy and the risk of severe coronavirus disease 2019 outcomes: a systematic review, meta-analysis, and meta-regression Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival Dementia and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: a systematic review and meta-analysis Determinants of COVID-19-related lethality in multiple sclerosis: a meta-regression of observational studies Risk factors of severe COVID-19 in people with multiple sclerosis: a systematic review and meta-analysis Multiple sclerosis and SARS-CoV-2 vaccination: considerations for immune-depleting therapies. Vaccines (Basel) COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies A plea for equitable global access to COVID-19 diagnostics, vaccination and therapy: the NeuroCOVID-19 Task Force of the European Academy of Neurology Strategy to identify priority groups for COVID-19 vaccination: a population based cohort study Understanding COVID-19 vaccine hesitancy Understanding vaccine hesitancy in COVID-19 Diagnosing the determinants of vaccine hesitancy in specific subgroups: the guide to tailoring immunization programmes (TIP) Covid-19 vaccination hesitancy COVID-19 vaccine hesitancy on social media: building a public twitter data set of antivaccine content, vaccine misinformation, and conspiracies Functional disorders after COVID-19 vaccine fuel vaccination hesitancy Functional neurological disorder after vaccination: a balanced approach informed by history Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification Spectrum of neurological complications following COVID-19 vaccination Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection Neurological autoimmune diseases following vaccinations against SARS-CoV-2: a case series European stroke organization interim expert opinion on cerebral venous thrombosis occurring after SARS-CoV-2 vaccination Cerebral venous thrombosis developing after COVID-19 vaccination: VITT, VATT, TTS, and more Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia Vaccine hesitancy among people with multiple sclerosis COVID-19 vaccine take-up rate and safety in adults with epilepsy: data from a multicenter study in China Attitudes to being vaccinated against COVID-19: a survey of people with epilepsy in China COVID-19 vaccine hesitancy in adults with multiple sclerosis in the United States: a follow up survey during the initial vaccine rollout in 2021 SARS-CoV-2 vaccination in multiple sclerosis: a clearer picture for the time point during CD20 depleting therapy Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy Humoral immune response after the third SARS-CoV-2 mRNA vaccination in CD20 depleted people with multiple sclerosis. Vaccines (Basel) Barriers to vaccination among people with Parkinson's disease and implications for COVID-19 COVID-19 vaccination for persons with Parkinson's disease: light at the end of the tunnel? A survey of hesitancy and response to the COVID-19 vaccine among patients with epilepsy in Northeast China Factors associated with COVID-19 vaccine hesitancy among people with epilepsy in Lithuania Vaccination and multiple sclerosis in the era of the COVID-19 pandemic Case report: multiple sclerosis relapses after vaccination against SARS-CoV2: a series of clinical cases Clinical onset and multiple sclerosis relapse after SARS-CoV-2 infection Severe multiple sclerosis relapse after COVID-19 vaccination: a case report mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis COVID-19 vaccination in patients with multiple sclerosis: what we have learnt by A systematic review of cases of CNS demyelination following COVID-19 vaccination Guillain-Barre syndrome following COVID-19 vaccines: a scoping review Vaccination against SARS-CoV-2 in neuroinflammatory disease: early safety/tolerability data Willingness to be vaccinated against COVID-19: an exploratory online survey in a Portuguese cohort of multiple sclerosis patients The educational role of IBD nurses in Italy in vaccinations: do not miss the moment for COVID-19 Readability assessment of vaccine information: a systematic review for addressing vaccine hesitancy Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics EAN consensus statement for management of patients with neurological diseases during the COVID-19 pandemic The international European Academy of Neurology survey on neurological symptoms in patients with COVID-19 infection COVID-19 vaccination hesitancy among people with chronic neurological disorders: A position paper Raw data can be provided on reasonable request.